Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.43 |
| ▸ | IP6K3 | Q96PC2 | 2/20 | 0.43 |
| ▸ | IP6K2 | Q9UHH9 | 2/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5138199 | 0.91 | SMN1; SMN2 (0.48) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL5138997 | 0.88 | PIM1 (0.49) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL5139037 | 0.87 | MEN1 (0.39) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL5200816 | 0.83 | IP6K1 (0.37) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL5138504 | 0.82 | DYRK1A (0.46) | ALDH1A1HPGDNPC1RAB9APKM | |
| SCHEMBL5930941 | 0.80 | TGFBR1 (0.38) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL27648467 | 0.80 | TGFBR1 (0.48) | NPC1RAB9APKMHSP90AA1L3MBTL1 | |
| Gw679410X SCHEMBL376414 | 0.80 | TGFBR1 (0.63) | NPC1RAB9APKMHSP90AA1L3MBTL1 | |
| SCHEMBL5138712 | 0.78 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL5138698 | 0.76 | PDE10A (0.49) | ALDH1A1HPGDTGFBR1SMN1; SMN2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | claimed |
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | BIOGEN IDEC MA INC. (US) | 2006-11-23 | — | — | US | claimed |
| EP-1596656-A4 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC INC (US) | 2006-10-18 | — | — | EP | claimed |
| JP-2006517592-A | — | — | 2006-07-27 | — | — | JP | claimed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1596656-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | Biogen Idec MA Inc. (US) | 2005-11-23 | — | — | EP | claimed |
| WO-2004072033-A2 | PYRAZOLES AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2004-08-26 | — | — | WO | claimed |
| WO-2008013928-A2 | TREATMENT OF CANCER WITH INTERFERON GENE DELIVERY IN COMBINATION WITH A TGF-BETA INHIBITOR | BIOGEN IDEC MA INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| EP-1804801-A2 | METHODS OF TREATING VASCULAR INJURIES | Biogen Idec MA, Inc. (US) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006044509-A2 | METHODS OF TREATING VASCULAR INJURIES | BIOGEN IDEC MA INC. (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264440-A1 | Pyrazoles and methods of making and using the same | ALK, ACVR1, ALKBH5 | MEN1 3811/4885KMT2A 1169/4885ALDH1A1 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.